|
|
|
|
| LEADER |
01648nam a2200289 u 4500 |
| 001 |
EB001865299 |
| 003 |
EBX01000000000000001029379 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
190504 r ||| eng |
| 245 |
0 |
0 |
|a Ivabradine hydrochloride (Lancora)
|h Elektronische Ressource
|
| 246 |
3 |
1 |
|a CDR clinical review report for Lancora
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2017, June 2017
|
| 300 |
|
|
|a 1 PDF file (65 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Ivabradine / adverse effects
|
| 653 |
|
|
|a Ivabradine / therapeutic use
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Cardiovascular Agents
|
| 653 |
|
|
|a Heart Failure / drug therapy
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review clinical review report
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK533838
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 700
|
| 520 |
|
|
|a The objective of this review was to perform a systematic review of the beneficial and harmful effects of ivabradine 5 mg and 7.5 mg tablets for the treatment of stable chronic heart failure (HF) with left ventricular ejection fraction (LVEF) (d 35%) in adult patients with New York Heart Association (NYHA) class II or III HF who are in sinus rhythm with a resting heart rate e 77 bpm, to reduce the incidence of cardiovascular mortality and hospitalizations for worsening HF, administered in combination with standard chronic HF therapies
|